D&D Pharmatech Past Earnings Performance
Past criteria checks 2/6
D&D Pharmatech's earnings have been declining at an average annual rate of -18%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 62% per year. D&D Pharmatech's return on equity is 6.2%, and it has net margins of 21.1%.
Key information
-18.0%
Earnings growth rate
-4.2%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 62.0% |
| Return on equity | 6.2% |
| Net Margin | 21.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How D&D Pharmatech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 18,677 | 3,934 | 8,427 | 19,973 |
| 30 Sep 23 | 17,002 | -90,520 | 8,461 | 25,672 |
| 31 Dec 22 | 611 | -136,067 | 9,287 | 47,125 |
| 31 Dec 21 | 1,364 | -68,224 | 8,823 | 56,826 |
| 31 Dec 20 | 0 | -63,406 | 7,353 | 50,805 |
| 31 Dec 19 | 0 | -6,359 | 4,010 | 19,550 |
| 31 Dec 18 | 348 | -20,002 | 1,336 | 188 |
Quality Earnings: A347850 has a high level of non-cash earnings.
Growing Profit Margin: A347850 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A347850 has become profitable over the past 5 years, growing earnings by -18% per year.
Accelerating Growth: A347850 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: A347850 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A347850's Return on Equity (6.2%) is considered low.